These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29852223)

  • 21. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcellular drug targeting, pharmacokinetics and bioavailability.
    Leucuta SE
    J Drug Target; 2014 Feb; 22(2):95-115. PubMed ID: 24188545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery of oligonucleotides with lipid nanoparticles.
    Wang Y; Miao L; Satterlee A; Huang L
    Adv Drug Deliv Rev; 2015 Jun; 87():68-80. PubMed ID: 25733311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
    Plane G
    IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic mRNA delivery to leukocytes.
    Granot-Matok Y; Kon E; Dammes N; Mechtinger G; Peer D
    J Control Release; 2019 Jul; 305():165-175. PubMed ID: 31121277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation.
    Scomparin A; Polyak D; Krivitsky A; Satchi-Fainaro R
    Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1294-309. PubMed ID: 25916823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.
    Garofalo M; Grazioso G; Cavalli A; Sgrignani J
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32290224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymersome-based drug-delivery strategies for cancer therapeutics.
    Anajafi T; Mallik S
    Ther Deliv; 2015; 6(4):521-34. PubMed ID: 25996048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic considerations for targeted drug delivery.
    Yamashita F; Hashida M
    Adv Drug Deliv Rev; 2013 Jan; 65(1):139-47. PubMed ID: 23280371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.
    Hazan-Halevy I; Landesman-Milo D; Rosenblum D; Mizrahy S; Ng BD; Peer D
    J Control Release; 2016 Dec; 244(Pt B):149-156. PubMed ID: 27491881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Materials for non-viral intracellular delivery of messenger RNA therapeutics.
    Kauffman KJ; Webber MJ; Anderson DG
    J Control Release; 2016 Oct; 240():227-234. PubMed ID: 26718856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oligonucleotide delivery in cancer therapy.
    De Rosa G; De Stefano D; Galeone A
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1263-78. PubMed ID: 20977291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.
    Shen J; Lu GW; Hughes P
    Pharm Res; 2018 Sep; 35(11):217. PubMed ID: 30255364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-Response-Time Data Analysis: An Underexploited Trinity.
    Gabrielsson J; Andersson R; Jirstrand M; Hjorth S
    Pharmacol Rev; 2019 Jan; 71(1):89-122. PubMed ID: 30587536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans.
    Goto T; Tanida N; Yoshinaga T; Sato S; Ball DJ; Wilding IR; Kobayashi E; Fujimura A
    J Control Release; 2004 May; 97(1):31-42. PubMed ID: 15147802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.